핵의학

본문글자크기
  • 2022년 07월호
    [Ann Nucl Med.] Prediction of cardiac events following concurrent chemoradiation therapy for non-small-cell lung cancer using FDG PET

    전남의대 / 조상건, 김용협, 안성자*, 범희승*

  • 출처
    Ann Nucl Med.
  • 등재일
    2022 May
  • 저널이슈번호
    36(5):439-449. doi: 10.1007/s12149-022-01724-w. Epub 2022 Feb 17.
  • 내용

    바로가기  >

    Abstract
    Objective: No imaging biomarkers are available for the prediction of cardiac events following concurrent chemoradiation therapy (CCRT) for non-small-cell lung cancer (NSCLC). We evaluated whether F-18 fluorodeoxyglucose positron emission tomography (FDG PET) early after CCRT, in addition to cardiac dosimetry, could predict late cardiac events in NSCLC.

    Methods: We retrospectively enrolled 133 consecutive patients with locally advanced, unresectable stage III NSCLC, who underwent FDG PET early after CCRT and survived at least 6 months. The primary endpoint was cardiac event ≥ grade 2 according to the Common Terminology Criteria for Adverse Events (version 5.0). Myocardial FDG uptake was measured and its association with the risk of cardiac events was evaluated.

    Results: FDG PET was performed after a median interval of 11 days of completing CCRT. Overall, 42 (32%) patients experienced cardiac events during a median follow-up of 45 months. The mean heart dose, maximum left ventricular (LV) standardized uptake value (SUV), changes in maximum and mean LV SUV, right ventricular uptake, tumor stage, white blood cell count, and diabetes were associated with cardiac events in univariable analysis. In multivariable analysis, maximum LV SUV (cutoff > 12.84; hazard ratio [95% confidence interval] = 2.140 [1.140-4.016]; p = 0.018) was an independent predictor of cardiac events along with the mean heart dose (> 11.1 Gy; 3.646 [1.792-7.417]; p < 0.001) and tumor stage (IIIB; 1.986 [1.056-3.734]; p = 0.033). It remained predictive of cardiac events in those with higher mean heart dose but not in those with lower mean heart dose.

    Conclusions: Early FDG PET after CCRT for NSCLC could aid in predicting late cardiac events, especially in patients with higher mean heart dose.

     

     

    Affiliations

    Sang-Geon Cho #  1 , Yong-Hyub Kim #  2 , Hyukjin Park  3 , Ki Seong Park  1 , Jahae Kim  1 , Sung-Ja Ahn  4 , Hee-Seung Bom  5
    1 Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea.
    2 Department of Radiation Oncology, Chonnam National University Hwasun Hospital, 322, Seoyang-ro, Hwasun-gun, Jeonnam, 58128, Republic of Korea.
    3 Department of Cardiololgy, Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea.
    4 Department of Radiation Oncology, Chonnam National University Hwasun Hospital, 322, Seoyang-ro, Hwasun-gun, Jeonnam, 58128, Republic of Korea. ahnsja@jnu.ac.kr.
    5 Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, 322, Seoyang-ro, Hwasun-gun, Jeonnam, 58128, Republic of Korea. hsbom@jnu.ac.kr.
    # Contributed equally.

  • 키워드
    Cardiotoxicity; Fluorodeoxyglucose; Non-small-cell lung cancer; Positron emission tomography; Radiation therapy.
  • 편집위원

    비소세포폐암 환자를 대상으로 18F-FDG PET에서 얻은 영상정보로 방사선 및 항암치료를 시행한 환자에서 심장사건의 발생가능성을 예측하는 흥미로운 임상연구임. 방사선 및 항암치료를 시행 받은 후 조기에 시행된 영상에서 mean heart dose가 높은 것은 이후 심장사건의 가능성이 높을 수 있음을 보여준 임상연구임. 폐암관련 임상가, 심장관련 임상가 및 핵의학의사에게 관심을 끌 연구로 생각됨.

    덧글달기2022-06-23 14:21:58

  • 덧글달기
    덧글달기
       IP : 3.141.44.9

    등록